Hershey Medical Center ALS Clinic
Hershey, Pennsylvania, 17033, United States
NCT Number: NCT04889898
The investigators propose a longitudinal home study of ALS patients to measure the severity of speech and swallowing (bulbar) impairment via a smartphone-based, remote speech and swallow assessment (rSSA). The study is designed to assess the feasibility and validity of such a monitoring intervention. Furthermore, it is proposed that regular monitoring of these two bulbar processes may shed light on their co-evolution over the course of ALS.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hershey, Pennsylvania, 17033, United States
Most individuals with ALS experience bulbar function deterioration over the course of the disease which impacts their quality of life significantly. Furthermore, in some patients, bulbar symptoms are an initial presenting symptom of ALS. Identifying these changes, which may be rapid in some individuals, is complicated by the recent acceleration of virtual care delivery.
The investigators propose a longitudinal home study of ALS patients to assess bulbar progression via a smartphone-based, self-administered remote speech and swallow assessment (rSSA). The overall hypothesis is that this monitoring protocol can be used in a way that, 1) is satisfactory to the patient, 2) performs at least as well as standard clinical measures of dysarthria and dysphagia, and 3) resolves the development of emergence of speech and swallowing pathologies in ALS.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients
Listeners
Exclusion criteria
Patients
Listeners
[Patients only] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
[Patients only] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
Other names: Videofluoroscopic Swallowing Study (VFSS)
[Patients only] The SIT is a standardized test for measuring speech intelligibility.
[Listeners only] Listeners will judge the intelligibility of speech recordings made by patients in the study.
Time frame: weekly for 24 weeks
Audio recordings of speech tasks and spontaneous swallowing task
Time frame: Weeks 0 and 24
Standardized scoring for the MBSS in 17 domains. Domains are aggregated in to scores for Oral Impairment (0-22), Pharyngeal Impairment (0-29), and Esophageal Impairment (0-4), with higher scores indicating impaired function.
Time frame: Weeks 0, 12, and 24
Listeners will score the intelligibility of patient SIT recordings
Time frame: Weeks 0, 12, and 24
ALS Specific Assessment of physical function ranging from 0-48, with 48 being normal function.
Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24
Self-administered rating scale for speech (7-49) and salivation (7-35) functions, with high scores indicating impaired function.
Time frame: Weeks 0, 12, and 24
A standard clinical swallowing assessment performed by the speech-language pathologist. Scores range from 38-200, with lower scores indicating higher impairment.
Time frame: Weeks 0, 12, and 24
A self-reported assessment of eating and swallowing function. Scores range from 0-40, with higher scores indicating higher impairment.
Time frame: Weeks 0, 12, and 24
A standard clinical respiratory assessment of vital capacity
Time frame: Weeks 0, 12, and 24
A standard clinical respiratory assessment of inspiratory strength
Milton S. Hershey Medical Center
Other
Home Telemonitoring of Bulbar Function by Acoustic Measurement of Swallowing and Speech Sounds in ALS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03192358
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Gainesville, Florida, United States
View Trial DetailsNCT03613038
Amyotrophic Lateral Sclerosis, Articulation Disorders
Fairway, Kansas, United States
View Trial DetailsNCT03560661
Amyotrophic Lateral Sclerosis, Articulation Disorders
Paris, France
View Trial DetailsNCT05724173
Amyotrophic Lateral Sclerosis, Anarthria
Stanford, California, United States
View Trial Details